Craig T Jordan

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Nat Clin Pract Oncol 2:224-5. 2005
  2. pmc Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data
    Duane C Hassane
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, NY, USA
    Blood 111:5654-62. 2008
  3. pmc Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia
    Benjamin J Frisch
    Endocrine Metabolism Division, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    Blood 119:540-50. 2012
  4. pmc Noncanonical NF-κB signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions
    Chen Zhao
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Stem Cells 30:709-18. 2012
  5. pmc Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 110:4436-44. 2007
  6. pmc In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells
    Benjamin J Frisch
    Endocrine Division, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Blood 114:4054-63. 2009
  7. pmc Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide
    Jolanta Skalska
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, United States of America
    PLoS ONE 4:e8115. 2009
  8. doi request reprint Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells
    John M Ashton
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    Cell Stem Cell 11:359-72. 2012
  9. doi request reprint How close are we to targeting the leukemia stem cell?
    Shanshan Pei
    University of Rochester School of Medicine, Wilmot Cancer Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 25:415-8. 2012
  10. pmc An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 110:4427-35. 2007

Collaborators

Detail Information

Publications44

  1. ncbi request reprint Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Nat Clin Pract Oncol 2:224-5. 2005
  2. pmc Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data
    Duane C Hassane
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, NY, USA
    Blood 111:5654-62. 2008
    ..These findings suggest the use of multicenter collections of high-throughput data to facilitate discovery of leukemia drugs and drug targets...
  3. pmc Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia
    Benjamin J Frisch
    Endocrine Metabolism Division, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    Blood 119:540-50. 2012
    ..Based on these results, we propose that therapeutic mitigation of leukemia-induced uncoupling of osteoblastic and osteoclastic cells may represent a novel approach to promote normal hematopoiesis in patients with myeloid neoplasms...
  4. pmc Noncanonical NF-κB signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions
    Chen Zhao
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Stem Cells 30:709-18. 2012
    ....
  5. pmc Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 110:4436-44. 2007
    ..We conclude that TDZD-8 uses a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations...
  6. pmc In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells
    Benjamin J Frisch
    Endocrine Division, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Blood 114:4054-63. 2009
    ..These novel effects of PGE(2) could be exploited clinically to increase donor ST-HSCs, which are highly proliferative and could accelerate hematopoietic recovery after stem cell transplantation...
  7. pmc Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide
    Jolanta Skalska
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, United States of America
    PLoS ONE 4:e8115. 2009
    ..Given recent data to suggest that the redox status of extracellular protein thiol groups (i.e. exofacial thiols) effects cell behavior, we hypothesized that redox active anti-cancer agents would modulate exofacial protein thiols...
  8. doi request reprint Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells
    John M Ashton
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    Cell Stem Cell 11:359-72. 2012
    ..We conclude that CRG-based analyses provide a powerful means to characterize the basic biology of LSCs as well as to identify improved methods for therapeutic targeting...
  9. doi request reprint How close are we to targeting the leukemia stem cell?
    Shanshan Pei
    University of Rochester School of Medicine, Wilmot Cancer Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 25:415-8. 2012
    ..The major mechanism of action of these small molecules appears to revolve around the aberrant glutathione metabolism pathway found in leukemic cells...
  10. pmc An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 110:4427-35. 2007
    ..Therefore, based on the collective preclinical data, we propose that the novel compound DMAPT has the potential to target human LSCs in vivo...
  11. doi request reprint Leukemia stemness signatures step toward the clinic
    Michael W Becker
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Cell Stem Cell 9:185-6. 2011
    ..2011) describes analyses of functionally defined leukemia stem cell populations that provide new insights on the biology of human tumor populations and the potential use of stem cell-associated gene signatures for prognosis...
  12. pmc Leukemia stem cells in a genetically defined murine model of blast-crisis CML
    Sarah J Neering
    James P Wilmot Cancer Center, University of Rochester Medical Center, NY 14642, USA
    Blood 110:2578-85. 2007
    ..Taken together, the system provides a powerful means by which the in vivo behavior of LSCs versus HSCs can be characterized and candidate treatment regimens can be optimized for maximal specificity toward primitive leukemia cells...
  13. ncbi request reprint Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells
    Sang Woo Kim
    Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA
    Blood 111:1644-53. 2008
    ..Together, these results indicate that PKK plays a pivotal role in the survival of human DLBCL cells and represents a potential target for DLBCL therapy...
  14. pmc BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells
    Eleni D Lagadinou
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Cell Stem Cell 12:329-41. 2013
    ..Based on these findings, we propose a model wherein the unique physiology of ROS-low LSCs provides an opportunity for selective targeting via disruption of BCL-2-dependent oxidative phosphorylation...
  15. doi request reprint A phase I study of decitabine and rapamycin in relapsed/refractory AML
    Jane L Liesveld
    Department of Medicine, Division of Hematology Oncology, University of Rochester, Rochester, NY 14642, United States Electronic address
    Leuk Res 37:1622-7. 2013
    ..This trial is registered at clinical trials.gov as NCT00861874...
  16. pmc A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors
    Christopher R Silvers
    Department of Urology, University of Rochester School of Medicine, Rochester, New York, USA
    Prostate 70:1379-87. 2010
    ..In order to help circumvent this challenge, we sought to develop an in vitro assay of human prostate cancer initiation employing a prostate-associated mesenchymal feeder layer...
  17. pmc The leukemic stem cell
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 20:13-8. 2007
    ..This article summarizes recent findings in the leukemic stem cell field and discusses new directions for therapy...
  18. pmc High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells
    Faith M Young
    Department of Medicine, University of Rochester, Rochester, New York, USA
    Biol Blood Marrow Transplant 14:622-30. 2008
    ..Thus, ALLs with INK4A/ARF or bcr/abl mutations are not intrinsically resistant to allogeneic T cell responses, suggesting that active immunotherapies against mHA have the potential to control such acute lymphoblastic leukemias...
  19. ncbi request reprint Cancer stem cells
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA
    N Engl J Med 355:1253-61. 2006
  20. doi request reprint Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Cancer Cell 15:252-4. 2009
    ..In the current issue of Cancer Cell, a study by Santaguida et al. provides new insights into JunB's function and the genesis of myeloid disease...
  21. ncbi request reprint The potential of targeting malignant stem cells as a treatment for leukemia
    Craig T Jordan
    University of Rochester School of Medicine, 601 Elmwood Ave, Box 703 Rochester, NY 14642, USA
    Future Oncol 1:205-7. 2005
    ..This perspective article summarizes recent findings in the leukemia stem cell field and discusses new directions for therapy...
  22. doi request reprint Targeting myeloid leukemia stem cells
    Craig T Jordan
    Departments of Medicine and Biomedical Genetics and the James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Sci Transl Med 2:31ps21. 2010
    ..Here the current understanding of the LSC phenotype is described, and the potential application of antibody-based treatment regimens is discussed...
  23. doi request reprint Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines
    Jane L Liesveld
    Department of Medicine, Hematology Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA jane
    Cancer Invest 29:439-50. 2011
    ..Combinations with arsenic trioxide, sorafenib, and cytarabine demonstrated synergistic in vitro effects in AML cell lines...
  24. pmc Cancer stem cells: controversial or just misunderstood?
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Cell Stem Cell 4:203-5. 2009
    ..In this commentary, underlying points of contention are described with the aim of defining focal points for discussion and future consideration...
  25. doi request reprint Leukemia stem cells in 2010: current understanding and future directions
    Michael W Becker
    James P Wilmot Cancer Center, Division of Hematology Oncology, University of Rochester Medical Center, Rochester, NY 14642, United States
    Blood Rev 25:75-81. 2011
    ....
  26. pmc Can we finally target the leukemic stem cells?
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 21:615-20. 2008
    ..Parameters are suggested here to help identify and quantitate leukemic stem cells in the clinical context...
  27. doi request reprint Discovery of potent parthenolide-based antileukemic agents enabled by late-stage p450-mediated C-h functionalization
    Joshua N Kolev
    Department of Chemistry, University of Rochester, Rochester, New York 14627, United States of America
    ACS Chem Biol 9:164-73. 2014
    ....
  28. ncbi request reprint Searching for leukemia stem cells--not yet the end of the road?
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Cancer Cell 10:253-4. 2006
    ..Biological features of leukemia stem cells in this system challenge previous thinking in several ways and suggest an unexpected degree of heterogeneity among stem cells in various forms of leukemia...
  29. ncbi request reprint Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells
    Jonathan M Weber
    Endocrine Division, Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue Box 693 Rochester, NY 14642, USA
    Bone 39:485-93. 2006
    ....
  30. ncbi request reprint Cancer stem cell biology: from leukemia to solid tumors
    Craig T Jordan
    Division of Hematology Oncology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 703, Rochester, New York 14642, USA
    Curr Opin Cell Biol 16:708-12. 2004
    ..Hence, a detailed understanding of stem cells and how they mediate tumor pathogenesis will be critical in developing more effective cancer therapies...
  31. pmc The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells
    Monica L Guzman
    University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA
    Blood 105:4163-9. 2005
    ..On the basis of these findings, we propose that the activity of PTL triggers LSC-specific apoptosis and as such represents a potentially important new class of drugs for LSC-targeted therapy...
  32. pmc Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels
    Ivan Topisirovic
    Institute for Research in Immunovirology and Cancer, University of Montreal, Montreal, Quebec H3T 1J4, Canada
    Mol Cell Biol 25:1100-12. 2005
    ....
  33. pmc Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency
    Felicia D Goodrum
    Department of Molecular Biology, Princeton University, Princeton, NJ 80544, USA
    Proc Natl Acad Sci U S A 99:16255-60. 2002
    ..Some of these expressed viral genes may function in latency and are targets for further analysis. Altered gene expression in hematopoietic progenitors may be indicative of the nature and outcome of HCMV infection...
  34. pmc Preferential induction of apoptosis for primary human leukemic stem cells
    Monica L Guzman
    Blood and Marrow Transplant Program, Markey Cancer Center, Division of HematologyOncology, University of Kentucky Medical Center, Lexington, KY 40536 0093 USA
    Proc Natl Acad Sci U S A 99:16220-5. 2002
    ..Further, the data begin to elucidate the molecular mechanisms that underlie LSC-specific apoptosis and suggest new directions for AML therapy...
  35. ncbi request reprint Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias
    Shimei Gong
    Department of Pediatrics, University of Kentucky, Lexington, KY 40536, USA
    Exp Hematol 30:1162-9. 2002
    ..We sought to identify OCT genes preferentially expressed in hematopoietic cells...
  36. ncbi request reprint Considerations for targeting malignant stem cells in leukemia
    Monica L Guzman
    Blood and Marrow Transplant Program, Markey Cancer Center, Division of Hematology Oncology, University of Kentucky Medical Center, Lexington, Kentucky, USA
    Cancer Control 11:97-104. 2004
    ..Like normal stem cells, these leukemic stem cells (LSCs) are able to self-renew, differentiate, and proliferate extensively. Evidence suggests that LSCs are critical for the initiation and perpetuation of leukemic disease...
  37. ncbi request reprint The hematopoietic stem cell in myelodysplasia
    Jane L Liesveld
    Leukemia Blood and Marrow Transplant Program, Rochester, NY, USA
    Stem Cells 22:590-9. 2004
    ....
  38. ncbi request reprint Mechanisms controlling pathogenesis and survival of leukemic stem cells
    Craig T Jordan
    Department of Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 703, NY 14642, USA
    Oncogene 23:7178-87. 2004
    ..In this review, we discuss emerging concepts in the field and describe how various molecular and cellular characteristics of leukemia cells might be exploited as a means to preferentially ablate malignant stem cells...
  39. ncbi request reprint A new approach to treatment of acute myelogenous leukemia using targeted therapy in combination with standard chemotherapy
    Craig T Jordan
    Leuk Res 28:1121-2. 2004
  40. ncbi request reprint Feverfew: weeding out the root of leukaemia
    Monica L Guzman
    Expert Opin Biol Ther 5:1147-52. 2005
    ..Thus, this naturally occurring agent may provide new avenues of investigation for the treatment of leukaemia. In this article, characteristics of parthenolide are reviewed...
  41. ncbi request reprint Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice
    Meredith A Bostrom
    Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY, USA
    Arterioscler Thromb Vasc Biol 27:600-6. 2007
    ..However, there is no direct evidence that this enzyme promotes atherogenic processes in vivo...
  42. pmc Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis
    Ivan Topisirovic
    Structural Biology Program, Department of Physiology and Biophysics, Mount Sinai School of Medicine, New York University, One Gustave Levy Place, New York, NY 10029, USA
    Mol Cell Biol 23:8992-9002. 2003
    ..Thus, our findings indicate that this nuclear function of eIF4E can contribute to leukemogenesis by promoting growth and by impeding differentiation...
  43. ncbi request reprint Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations
    Felicia Goodrum
    Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
    Blood 104:687-95. 2004
    ....
  44. doi request reprint The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Blood 111:4681-9. 2008
    ..001, r(2) = 0.3), implicating Rel A in fludarabine resistance. Taken together, these data indicate that Rel A represents an excellent therapeutic target for this incurable disease...